Guest Lineup Announced with 10 Days to Go: 2023 Pharmaceutical Innovation Compass Conference – Investment & BD Partnership

Conference Collaboration |Ms. Dong 15310303571

Conference Registration |Capillaries 17782369627 (WeChat ID same as phone number)

Over the past decade, the rise of China’s biotech sector and the transformation and upgrading of domestic enterprises have laid the foundation for infrastructure development and pilot initiatives in the country’s pharmaceutical innovation industry. Amidst shifting international dynamics and economic cycles, the rules governing venture capital investment in pharmaceutical innovation are undergoing volatile adjustments. The ecosystem for innovative drugs in China is experiencing profound and far-reaching changes, breaking down the self-contained systems of Biotech and Pharma companies. The new arena for innovation requires concerted collaboration among Biotech firms, Pharma companies, capital investors, and new infrastructure.

The zeitgeist of reshaping, adjustment, and uncertainty is projected onto every enterprise and individual. Yet we can “continuously break the shackles of conventional thinking and seek pathways that connect all things,” evolving and advancing together.

“2023 Pharmaceutical Innovation Trend Conference · Investment and BD Partnership” will be held in Suzhou on October 21, the conference is dedicated to fostering integration and exchange among biotech, pharma, capital, and new infrastructure sectors, enabling attendees to “meet new people and gain new insights.” It provides scarce networking value and has become a trusted barometer for venture capital investment and business development (BD) partnerships in China’s innovative drug industry.

Co-organized by: VCBeat New Medicine, Qinshan Subdistrict Office

Forum Planning: Qinshan Subdistrict Office,Wu Chao | General Manager, VBInsight

■ 09:00–09:05 Opening Remarks & Kick-off by the Organizer

Moderator: Zhu Xueqi |VCBeat Medicine Editor-in-Chief

■ 09：05-09：25  Keynote Speech

New Issues and Trends Emerging from the Deep-Water Zone of Radiopharmaceutical Development

Guo Sizhou | Investment Director, Shijie Capital

■ 09：25-10：20  Panel 1

Pioneers in Radiopharmaceuticals: Perspectives on Building, Promoting, and Intergenerational Synergy in China’s Radiopharmaceutical Ecosystem

Host: Wu Haowei | CEO, Midu Biotech

Novartis

Jiyun Sun | Director of Radiopharmaceutical R&D, Yunnan Baiyao Innovative Drug Center

Xie Zhiqian | Dongcheng Pharmaceutical, Commercial Director

Bai Ge | COO, Guotong New Drug

Wang Xiaolei | Senior Director, Neurita Institute for Drug Research

Hui Qi | General Manager, China, Fulian Technology

Yu Haihua | Co-founder and CEO of Crystal Nucleus Biotechnology

Wang Guanli | CEO of Sitikangchen

■ 10:20–10:40 Keynote Address

Introduction to the Nuclear Technology Application Industry in Haiyan County

Qinshan Subdistrict Office

■ 10：40-11：10  Panel 2

Three Investors Who Focused on Radiopharmaceuticals at Different Times Share Insights on “How to Invest, What to Invest In, and How to Find Opportunities”

Host: Zhu Xueqi | Editor-in-Chief, VCBeat Pharma

Li Jia | Partner, Longsheng Investment

Liu Chuanwen | Partner, Xinjun Capital

Guo Sizhou | Investment Director, Shijie Ventures

■ 11:10-11:30 Keynote Speech

Gaining Insights into Potential Effective Development Strategies from Several Radiopharmaceutical Development Cases

Bai Ge | COO, Guotong New Drug

■ 11：30-12：00

Underwater Project Showcase + Open Mic Discussion

Project Debut:

Hong Hao | CTO, Sitikangchen

Peng Kun | Deputy General Manager (Partner), Morick Biotech

Featured Guest Speaker:

Miao Huilei | Clinical Research Physician, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences

Shuai Song | ADC Expert at Yilian Biologics

Co-organized by: VCBeat New Medicine, Xingcheng Biotechnology

Forum Planning: Liu Xiao | Vice President of Business, Hangzhou Xingcheng Biotechnology Co., Ltd.Wu Chao | General Manager, Arterial New Medicine

■09:00-09:05 Organizer's Address & Opening Remarks

Moderator: Liu Xiao | Vice President of Business Development, Xingcheng Biotechnology

■ 09：05-09：30  Keynote Speech

Insights from CMC: The Pace and Trends of CGT Industry Upgrading

Wang Lijun | Co-founder and CEO, Xingcheng Biotechnology

■ 09：30-09：55  Keynote Speech

General Considerations for Nonclinical Efficacy Evaluation of Cell Therapy Products

Chen Haining | Deputy General Manager, Pharmacology and Efficacy Center, Saifu Pharma

■ 09:55-10:20 Keynote Speech

Patent Portfolio Strategy for Cell and Gene Therapy

Tang Huadong | Partner, Beijing Zhide Law Firm

■ 10:20-10:45 Keynote SpeechLecture

Examining Product Initiation and BD Considerations Through the Commercialization Pathway of CGT Products

Wang Zhengjue | Deputy General Manager, Sinopharm Holding Innovation Center

■ 10：45-12：00

Underwater Project Showcase + Open Mic Discussion

Project Debut:

Yang Hanshuo | Chairman, Zhenyu Biotech

Song Xu | Founder of LingTaiKe

Yu Qing | VP of R&D, Yuandao Biology

Featured Guest Speaker:

Liang Yanyan | Co-founder and COO, Xingchen Zhiyao

Liu Yueguang | Co-founder and CSO, Nurenbio

Cheng Jinsheng | Vice President of Tofflon Group, General Manager of Life Science Division

Xu Rong | Tongli Haiyuan Biotechnology, Vice President of Technology

Xu Chong | Director of Key Account Sales, Danaher Life Sciences Platform

Binhu Bio (ing

RuiZheng Gene (ing

Wang Xiaoyan | Partner, Jinsha River United Runpu Medical Fund

Wang Haotian | Legend Capital, Vice President of Investment

Co-organized by: VBNewMed CTIC CAPITAL

Forum Planning: Du Juan | Partner, CTIC CAPITAL; Hongfeng InvestmentWu Chao | General Manager, VCBeat New Medicine

■09:00-09:05 Opening Remarks by the Host

Host: Niu Hongsen | CEO, SUBIA Corporation

■ 09:05-09:25 Keynote Speech

How BD Can Play a Greater Role in the Current Financing Environment

Peter Ho | CTIC CAPITAL

■ BD Case Sharing and Open Discussion

09：25-09：45

BD Experience Sharing by Large Pharmaceutical Companies in Response to the Current Financing Challenges in the Pharmaceutical Industry

Jiang Dawei | Director, Business Development, Global R&D Collaboration Department, Shanghai Pharmaceuticals Group

09：45-10：05

How Biotech Companies Can Achieve Commercial Breakthroughs and Self-Sustaining Revenue Generation

Hong Jun | Vice President, Global Business Development, I-Mab

10：05-10：25

Title TBD

Wei Wu | Head of Strategic Investments, Asia Pacific, Johnson & Johnson

10：25-10：45

How Business Development Can Achieve a 1+1>2 Effect in the Early Stages of Biotech Startups

Wu Hongzhong | Head of Strategic Partnerships and Business Development, Molecular Mind

10：45-11：05

CROs Help Biotech Navigate Economic Cycles, Weather the Trough, and Achieve Glory

Zhang Yanhong | Chief Strategy Officer, Boji Medicine; Partner, Boji Venture Capital

11：05-11：25

Examining Legal Risks in BD Transactions Through an Endgame Mindset

Yuan Liming | Partner, Han Kun Law Offices

11：25-11：45

Returning to the BD Function: Revisiting the Fundamentals of Business Management

Liang Yuhai | General Manager, Suzhou Hanmeng Management Consulting

11：45-12：00

Challenges and Countermeasures for Business Development in the New Financing Environment

Du Juan | Partner, CTIC Capital & Hongfeng Investment

Topic Initiator: Mou Lei | Senior Researcher at VCBeat

Lu Qiwen | Director, BFC GroupGao Yunan | Managing Director, BFC Group

Huang Jinglin | Senior Director of Strategy, Tengmai PharmaXiao Liu | Vice President of Business and Marketing, Hangzhou Xingcheng Biotechnology Co., Ltd.

Chief Planner: Wu Chao | General Manager, VCBeat New MedicineWei Linlin | Deputy General Manager, VB100

■13:30-14:00 Band Performance

Rose Wine Seat

■14:00-14:05 Opening Remarks & Kick-off by the Organizer

Organizer：Li Datao | Founder of VCBeat

Moderator: Zhang Haiyang | Senior Researcher, VCBeat Orange Bureau

■14：05-14：45  Panel 1-Investing in Evergreens

Capital-Rich but Time-Poor: Where Do the Trends Lie for GPs and State-Owned Investors Evaluating Projects?

Moderator: Mou Lei | Senior Researcher at VCBeat

Hu Hongdan | Executive Director, Mifang Health Fund

Yang Shujun | Legend Capital, Investment Director

Chen Wei | Investment Director, Sichuan Development Hongke Equity Investment Fund Management

Ji Qianqian | Senior Investment Manager, Shenzhen High-Tech Investment

■ 14：45-15：30  Panel 2-BD Kickoff

Where Are Innovative Drug Companies Headed: License-in or License-out? Leveraging the Tailwinds of Business Development to Navigate Market Cycles

Moderator: Lu Qiwen | Director, BFC Group

Huang Li | Director of Investment and M&A, GenSci Pharmaceutical

Jiang Dawei | Director, Business Development, Global R&D Collaboration Department, Shanghai Pharmaceuticals Group

Pan Yu | Director of Business Development and Head of BD, Jacobio Pharmaceuticals

Hong Jun | Vice President, Global Business Development, I-Mab Biopharma

■15：30-16：15  Panel 3: AI Ramp-Up

As an AI-driven new drug developer, what other ecosystem partners do we need besides pharmaceutical companies on our evolutionary journey?

Moderator: Huang Jinglin | Senior Strategic Director, Tengmai Pharma

Hu Yonghan | Chief Technology Officer, Sinocelltech

Ding Yuanhua | Co-founder, Yuanqi Bio

Guo Chunlong | CEO of Shuimu Future

Wang Bo | Vertex Capital

Hanzandi (ing

■ 16：15-17：00  Panel 4: Rationality in New Infrastructure

Starting from CMC: How to Rationally View Collaborations with Domestic and Overseas Enterprises?

Moderator: Liu Xiao | Vice President of Business Development, Xingcheng Biotechnology

Wang Lijun | Co-founder and CEO of Xingcheng Biotech

Xu Rong | Tongli Haiyuan Biotechnology, Vice President of Technology

HuaLi Qiang | Global Vice President and General Manager of China, Replicel

Xu Chong | Key Account Sales Director, Danaher Life Sciences Platform

Zou Yang | Vice President of R&D, Lepu Biopharma

Representative Organizations of the Audience:

Gonex, Innorna, N1 Life, Danxu Biotech, Bohe Innovation Center, Chenling Capital, Enshe Family Office, Henlius, Fuyi Capital, Hankang Capital, Baicheng Medicine, Langyu Capital, Nan'an Xindi, Dynamic Balance Investment, Triastek, Puwang Biotech, Qilu Pharmaceutical, Qingtong Capital, Licai Pharma, Guotai Junan, Jinkebo Biotech, Shanghai Frontier Industry Innovation Center for Biomedicine, Shanghai Yaotan, Sinopep-Allsino, Borui Chuanghe, Xianglong Biotech, Teva Pharmaceuticals, Tianchao Capital, Tasly Capital, YZY Biopharma, Xilin Investment, Xincheng Fund, Xingyiang Biotech, Yafa Capital, Ascentage Pharma, Yangzijiang, Yunjiu Capital, Zhidao Capital, Zhimian Tech, Zhongrun Medicine

*The above organizations are listed in alphabetical order, with no ranking implied.